Literature DB >> 2528589

Differential regulation of murine B cell Fc gamma RII expression by CD4+ T helper subsets.

C M Snapper1, J J Hooley, U Atasoy, F D Finkelman, W E Paul.   

Abstract

The murine B cell FcR for IgG (Fc gamma RII) is a membrane glycoprotein reported to mediate inhibition of B cell activation and differentiation. We show that IL-4 inhibits the enhanced expression of Fc gamma RII by LPS-stimulated B cells. This activity is completely reversed by anti-IL-4 mAb and is specific, in that multiple other lymphokines tested do not exert a similar effect. This effect of IL-4 is apparent by day 1 of culture, although maximal inhibition occurs on day 4 at a concentration of 500 U/ml. The IL-4-induced inhibition of enhanced Fc gamma RII expression by LPS stimulation observed on day 4 of culture is associated with a significant reduction in the steady state level of Fc gamma RII beta gene-specific mRNA. IFN-gamma which inhibits many of the effects of IL-4 on B cells, does not reverse the IL-4-induced inhibition of Fc gamma RII membrane expression nor the levels of beta gene-specific mRNA. Fc gamma RII expression is significantly increased in B cells stimulated with antigen-specific, CD4+ T cell clones of the Th1 type (i.e., IL-2 and IFN-gamma-producing). By contrast, three different Th2 clones (i.e., IL-4-producing) fail to stimulate an increase in Fc gamma RII levels. Anti-IL-4 mAb significantly enhanced Fc gamma RII expression by Th2-stimulated B cells indicating that IL-4 was the active, inhibitory, substance produced by the Th2 cells. Supernatants from stimulated Th2 clones inhibited the enhanced expression of Fc gamma RII by LPS-stimulated B cells and this activity was completely reversed by anti-IL-4 mAb. By contrast, supernatants from stimulated Th1 clones further enhanced Fc gamma RII expression by LPS-stimulated B cells. The differential regulation of B cell Fc gamma RII expression by Th subsets may play an important role in the regulation of humoral immunity by altering the sensitivity of B cells to IgG immune complex-mediated inhibition of B cell activation and differentiation in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528589

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

2.  Inhibition of immunoglobulin E synthesis through Fc gammaRII (CD32) by a mechanism independent of B-cell receptor co-cross-linking.

Authors:  Jutta Horejs-Hoeck; Andrea Hren; Geert C Mudde; Maximilian Woisetschläger
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

Review 3.  FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

Authors:  Kenneth G C Smith; Menna R Clatworthy
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 4.  Regulation of the expression of murine alpha- and beta-Fc gamma R genes.

Authors:  M Daëron
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

5.  Expression of B-cell activating factor enhances protective immunity of a vaccine against Pseudomonas aeruginosa.

Authors:  Christine Tertilt; Ju Joh; Anja Krause; Paigee Chou; Kristin Schneeweiss; Ronald G Crystal; Stefan Worgall
Journal:  Infect Immun       Date:  2009-04-13       Impact factor: 3.441

Review 6.  Inhibitory Fc gamma receptors: from gene to disease.

Authors:  Radu N Stefanescu; Mikhail Olferiev; Yi Liu; Luminita Pricop
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

7.  Fc gamma receptors and cross-presentation in dendritic cells.

Authors:  Sebastian Amigorena
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

Review 8.  The Complex Association of FcγRIIb With Autoimmune Susceptibility.

Authors:  J Sjef Verbeek; Sachiko Hirose; Hiroyuki Nishimura
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.